CD4 and myeloid sarcoma: A putative weakness in this regulatory mechanism in MS has also been addressed by comparing intrathecal and peripheral CD4+ T-cell senescence in patients with MS and controls affected of other inflammatory and non-inflammatory neurological diseases.